NDAORALTABLET
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
LEQSELVI (deuruxolitinib phosphate) by PharmaIN is (jak) inhibitor. First approved in 2024.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQSELVI (deuruxolitinib phosphate) is an oral JAK inhibitor that selectively targets JAK1, JAK2, and TYK2 to modulate immune and hematopoietic signaling. The drug was approved by the FDA on July 25, 2024, and represents a novel mechanism for treating immune-mediated conditions through STAT-mediated gene expression modulation. Specific approved indications are not yet detailed in available data.
Growth18.1 years to LOE
Early-stage growth product with limited commercial data; commercial infrastructure and field teams likely still scaling post-approval.
Mechanism of Action
(JAK) inhibitor. JAKs mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEQSELVI represents a post-launch growth opportunity in a competitive JAK inhibitor space, with career roles focused on market penetration, physician engagement, and payer negotiation. The 18-year patent tail and early commercial stage create stability for mid-to-senior career advancement in specialty pharma.
Brand Manager
Worked on LEQSELVI at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.